Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma.

Aging - 20 Jun 2023

Liu Honggang, Xin Tao, Duan Hongtao, Wang Yuanyong, Shao Changjian, Zhu Yifang, Wang Jiansheng, He Jianjun

Abstract excerpt

Mucin 16 (MUC16) mutation ranks third among all common mutations in lung adenocarcinoma (LUAD), and it has a certain effect on LUAD development and prognostic outcome. This research aimed to analyze the effects of MUC16 mutation on LUAD immunophenotype regulation and determine the prognostic outcome using an immune prognostic model (IPM) built with immune-related genes. The MUC16 mutation status and mRNA...

Topics

Join the communities discussing this publication.

Adenocarcinoma of Lung
CA-125 Antigen
Lung Neoplasms
Membrane Proteins
Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 37341998
DOI: 10.18632/aging.204814
PMCID: PMC10333060

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma.PMID 37341998Read ↗

Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.Semantic proximity Read ↗

Validating S100A16 as a prognostic and immunological biomarker in pan-cancer and lung adenocarcinoma through integrated Single-cell Sequencing AnalysisSemantic proximity Read ↗

Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.Semantic proximity Read ↗

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.Semantic proximity Read ↗

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.Semantic proximity Read ↗

Expression signature, prognosis value, and immune characteristics of MUC1 identified by pan-cancer analysisSemantic proximity Read ↗

A Novel Prognostic Model of Early-Stage Lung Adenocarcinoma Integrating Methylation and Immune BiomarkersSemantic proximity Read ↗

Comprehensive pan-cancer analysis identified SLC16A3 as a potential prognostic and diagnostic biomarkerSemantic proximity Read ↗

High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations.Semantic proximity Read ↗

Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcomeSemantic proximity Read ↗

MECOM/PRDM3 and PRDM16 Serve as Prognostic-Related Biomarkers and Are Correlated With Immune Cell Infiltration in Lung AdenocarcinomaSemantic proximity Read ↗

METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.